Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy

This article was originally published here

BASIS is a global Phase 3, open-label, multicenter study that will evaluate annualized bleed rate (ABR) through 12 months on prophylaxis treatment with marstacimab, an investigational, novel subcutaneous

The post Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply